HONG KONG, 4 August 2025 – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology”, “Zhaoke” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company, is pleased to announce that the Company has obtained a National Medical Products Administration (“NMPA”) medical device registration certificate for TONO-i, a medical device for intraocular pressure (“IOP”) measurement.

TONO-i is an innovative tonometer designed to be contactless, portable, and convenient. Unlike conventional contact-type tonometer, TONO-i is safe to use without the need for anaesthesia, pain, or the risk of contamination.

TONO-i will become an integral part of the Company’s glaucoma franchise to address the unmet need of low diagnosis and treatment rates in China. It provides a tool for ophthalmologists to monitor patients’ IOP conveniently, accurately and thoroughly through measurement. It will likely improve patient compliance for glaucoma drug treatment by giving instant and continuous feedback on its efficacy. Inclusion of TONO-i in the Company’s glaucoma franchise signifies the Company’s commitment to glaucoma management in both treatment and diagnosis.

In November 2022, Zhaoke reached an exclusive distribution agreement on TONO-i with C&V Tech, a leading company in the development of medical devices for the diagnosis, treatment, and prevention of glaucoma. Under the terms of the agreement, the Company has exclusive rights to register, import, promote, distribute, market and sell TONO-i in Greater China, Thailand and Malaysia.

Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, commented, “NMPA’s endorsement of TONO-i marks another step forward in our commitment to combating glaucoma, one of the leading causes of irreversible blindness. We anticipate that this cutting-edge tonometer will transform clinical practice by enhancing screening accessibility across medical institutions, ultimately helping address the persistently low diagnosis and treatment rates of glaucoma in China.”

About Glaucoma

According to China Insights Consultancy, glaucoma, the second-leading cause of blindness worldwide, is a chronic and progressive disease associated with high IOP, resulting in optic nerve damage. The IOP is determined by the balance of the rate of fluid production versus fluid drainage in the eye. Most glaucoma cases are primary glaucoma, which can be generally classified into two types: open-angle glaucoma and angle-closure glaucoma.

China has the world’s largest number of glaucoma patients, accounting for approximately a quarter of all glaucoma patients worldwide. According to the Chinese Glaucoma Guidelines (2020), it is estimated that the number of glaucoma patients in China was 21.8 million in 2020 and 5.67 million patients will go blind. In addition, the diagnosis rate of glaucoma is expected to increase significantly from 20.0% in 2019 to 60.6% in 2030.

About C&V Tech

C&V Tech was founded by Dr. Jin-Hue Kang in Wonju, South Korea, in 2015. C&V Tech received significant investments from Daewoo Pharmaceutical Co. (“Daewoo Pharma”) as a strategic partner, and Dr. Yong-Hoon Ji, an ophthalmologist from Seoul National University and now the CEO of Daewoo Pharma. Dr. Kang, with over 25 years of experience in biotech research and entrepreneurship, including leading positions at the Samsung Medical Centre Life Science Research Institute, focused on glaucoma patient care and invented the self-measurable tonometer, TONO-i. Daewoo Pharma, with its specialization in ophthalmology, has assisted in the development of TONO-i by C&V Tech, and is actively marketing this innovative product internationally.

- End -